Pre-Test Targeted Strategies in the Management of Non-Small Cell Lung Cancer: A Focus on EGFR Gene Mutations Pre-Test The majority of EGFR mutations in NSCLC occur in which of the following locations? Exons 14-17 Exons 16-19 Exons 18-21 Exons 20-23 Unsure In patients with advanced EGFR-mutant NSCLC, primary results from the Phase 3 MARIPOSA-2 study revealed which of the following? Amivantamab–erlotinib–chemotherapy improved OS and intracranial PFS versus chemotherapy Amivantamab–lazertinib–chemotherapy demonstrated improved PFS versus chemotherapy after disease progression on osimertinib Erlotinib–chemotherapy demonstrated improved PFS versus chemotherapy after disease progression on osimertinib Lazertinib–chemotherapy improved OS and intracranial PFS versus chemotherapy Unsure Prior to amivantamab treatment, which of the following premedication strategies is required to reduce the risk of infusion-related reactions? Intravenous acetaminophen (1,500 mg) or equivalent Intravenous dexamethasone (20mg) or equivalent Oral acetaminophen (1,500 mg) Oral dexamethasone (20mg) Unsure How confident are you in your ability to mitigate, manage, and anticipate adverse events associated with EGFR-targeted therapies? Very confident Confident Somewhat confident Not very confident Not at all confident
